Pros and cons of streamlining and use of computerised clinical decision support systems to future-proof oncological multidisciplinary team meetings.
computerized clinical decision support systems
multidisciplinary team meeting
oncology
oncology care
streamlining
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
02
03
2023
accepted:
27
04
2023
medline:
5
6
2023
pubmed:
5
6
2023
entrez:
5
6
2023
Statut:
epublish
Résumé
Nowadays nearly every patient with cancer is discussed in a multidisciplinary team meeting (MDTM) to determine an optimal treatment plan. The growth in the number of patients to be discussed is unsustainable. Streamlining and use of computerised clinical decision support systems (CCDSSs) are two major ways to restructure MDTMs. Streamlining is the process of selecting the patients who need to be discussed and in which type of MDTM. Using CCDSSs, patient data is automatically loaded into the minutes and a guideline-based treatment proposal is generated. We aimed to identify the pros and cons of streamlining and CCDSSs. Semi-structured interviews were conducted with Dutch MDTM participants. With purposive sampling we maximised variation in participants' characteristics. Interview data were thematically analysed. Thirty-five interviews were analysed. All interviewees agreed on the need to change the current MDTM workflow. Streamlining suggestions were thematised based on standard and complex cases and the location of the MDTM (i.e. local, regional or nationwide). Interviewees suggested easing the pressure on MDTMs by discussing standard cases briefly, not at all, or outside the MDTM with only two to three specialists. Complex cases should be discussed in tumour-type-specific regional MDTMs and highly complex cases by regional/nationwide expert teams. Categorizing patients as standard or complex was found to be the greatest challenge of streamlining. CCDSSs were recognised as promising, although none of the interviewees had made use of them. The assumed advantage was their capacity to generate protocolised treatment proposals based on automatically uploaded patient data, to unify treatment proposals and to facilitate research. However, they were thought to limit the freedom to deviate from the treatment advice. To make oncological MDTMs sustainable, methods of streamlining should be developed and introduced. Physicians still have doubts about the value of CCDSSs.
Identifiants
pubmed: 37274246
doi: 10.3389/fonc.2023.1178165
pmc: PMC10233094
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1178165Informations de copyright
Copyright © 2023 Walraven, Verhoeven, van der Hoeven, van der Meulen, Lemmens, Hesselink and Desar.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
BMC Cancer. 2020 Apr 28;20(1):355
pubmed: 32345242
Australas Radiol. 2004 Dec;48(4):487-92
pubmed: 15601329
J Eval Clin Pract. 2013 Dec;19(6):1035-43
pubmed: 23441961
JCO Clin Cancer Inform. 2021 Feb;5:187-193
pubmed: 33571000
Cancer Nurs. 2021 Nov-Dec 01;44(6):E476-E492
pubmed: 33913442
Eur J Oncol Nurs. 2021 Oct;54:102032
pubmed: 34597962
Anesthesiology. 2019 Jul;131(1):14-22
pubmed: 31045898
Asia Pac J Clin Oncol. 2018 Feb;14(1):74-83
pubmed: 28949100
Lancet Oncol. 2005 Oct;6(10):738
pubmed: 16229093
BMJ Open Qual. 2019 Jun 4;8(2):e000631
pubmed: 31259288
J Biomed Inform. 2013 Aug;46(4):744-63
pubmed: 23806274
Qual Health Res. 2015 Mar;25(3):397-407
pubmed: 25281239
J Multidiscip Healthc. 2021 Jun 04;14:1311-1324
pubmed: 34113119
Cancer Treat Rev. 2016 Jan;42:56-72
pubmed: 26643552
World J Surg Oncol. 2018 Jul 19;16(1):146
pubmed: 30025532
Eur J Cancer. 2022 Aug;171:13-21
pubmed: 35696885
Implement Sci. 2018 Aug 20;13(1):114
pubmed: 30126421
Cancer Med. 2020 Oct;9(19):7083-7099
pubmed: 32794351
Br J Surg. 2021 Apr 30;108(4):e162-e163
pubmed: 33778851
BJU Int. 2021 Sep;128(3):271-279
pubmed: 34028162
Cancer Med. 2020 Jul;9(14):5143-5154
pubmed: 32476281
Cancers (Basel). 2021 Aug 18;13(16):
pubmed: 34439312
AMIA Annu Symp Proc. 2007 Oct 11;:656-60
pubmed: 18693918
BMC Health Serv Res. 2021 Oct 1;21(1):1032
pubmed: 34592971
Ann Intern Med. 2012 Jul 3;157(1):29-43
pubmed: 22751758
BMC Med Educ. 2022 Jun 27;22(1):502
pubmed: 35761247
BMC Health Serv Res. 2022 Jun 27;22(1):829
pubmed: 35761282
BMJ Open. 2012 Jun 25;2(3):
pubmed: 22734113
J Clin Neurosci. 2010 Sep;17(9):1130-5
pubmed: 20570520
Biomed Res Int. 2021 May 01;2021:5541613
pubmed: 33997003
Biology (Basel). 2020 Dec 25;10(1):
pubmed: 33375573
BMJ Open Qual. 2023 Feb;12(1):
pubmed: 36759037
World J Surg. 2019 Feb;43(2):559-566
pubmed: 30382292
Br J Cancer. 2021 Jan;124(2):368-374
pubmed: 32989229
Br J Oral Maxillofac Surg. 2014 Feb;52(2):128-33
pubmed: 24280116
Eur J Surg Oncol. 2021 Oct;47(10):2682-2688
pubmed: 34127326
Adm Policy Ment Health. 2015 Sep;42(5):533-44
pubmed: 24193818
Cancers (Basel). 2020 Apr 22;12(4):
pubmed: 32331449
Front Psychol. 2019 Jul 09;10:1245
pubmed: 31354555
Am Soc Clin Oncol Educ Book. 2014;:e461-6
pubmed: 24857140
Br J Hosp Med (Lond). 2020 Mar 2;81(3):1-6
pubmed: 32239992
BMJ Open. 2019 May 27;9(5):e027303
pubmed: 31138582
Clin Med (Lond). 2014 Aug;14(4):338-41
pubmed: 25099829
BMJ Qual Saf. 2021 Oct;30(10):792-803
pubmed: 33247002